Prognostic Significance of High Mobility Group Box 1 (HMGB1) Expression in Patients with Colorectal Cancer

Overview

Journal Anticancer Res

Specialty Oncology

Date 2014 Oct 3

PMID 25275029

Citations 21

Authors

Masami Ueda

Yusuke Takahashi

Yoshiaki Shinden

Shotaro Sakimura

Hidenari Hirata

Ryutaro Uchi

Yuki Takano

Junji Kurashige

Tomohiro Iguchi

Hidetoshi Eguchi

Keishi Sugimachi

Hirofumi Yamamoto

Yuichiro Doki

Masaki Mori

Koshi Mimori

Affiliations

Soon will be listed here.

Abstract

Background: High mobility group 1 (HMGB1) is a highly conserved non-histone nucleosomal protein in mammals. We investigated the clinical significance of HMGB1 expression in colorectal cancer (CRC).

Patients And Methods: The expression of HMGB1 mRNA in 140 tumor and normal tissues from CRC patients was examined by quantitative real-time polymerase chain reaction (PCR). We immunohistochemically investigated HMGB1 expression in tumor and metastatic lymph nodes in CRC.

Results: HMGB1 expression was significantly higher in tumor than in normal tissues. High HMGB1 expression was associated with larger tumor volumes, higher rates of lymphatic invasion, more frequent lymph node metastases and poorer prognoses for overall survival. Multivariate analyses showed that HMGB1 expression was an independent prognostic indicator of overall survival. Immunocytochemical analysis revealed that HMGB1 was overexpressed in both CRC tissues and regional lymph node metastases.

Conclusion: Investigating HMGB1 expression may be a predictor of postoperative lymph node metastasis and prognosis in CRC.

Citing Articles

Immunogenic cell death in colorectal cancer: a review of mechanisms and clinical utility.

De Silva M, Tse B, Diakos C, Clarke S, Molloy M Cancer Immunol Immunother. 2024; 73(3):53.

PMID: 38353760 PMC: 10866783. DOI: 10.1007/s00262-024-03641-5.

The expression of high mobility group protein 3 () in breast cancer with emphasis on its role in lymphovascular invasion.

Aljohani A, Alsaeed S, Toss M, Raafat S, Green A, Rakha E Am J Cancer Res. 2023; 13(11):5334-5351.

PMID: 38058796 PMC: 10695817.

miR-495-3p depresses cell proliferation and migration by downregulating HMGB1 in colorectal cancer.

Zhang J, Zheng H, Li K, Zhu Y World J Surg Oncol. 2022; 20(1):101.

PMID: 35354479 PMC: 8966301. DOI: 10.1186/s12957-022-02500-w.

HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity.

Liao Y, Liu S, Fu S, Wu J Onco Targets Ther. 2020; 13:6859-6871.

PMID: 32764978 PMC: 7369309. DOI: 10.2147/OTT.S253772.

HMGB1: an overview of its versatile roles in the pathogenesis of colorectal cancer.

Cheng K, Alshawsh M, Mohamed E, Thavagnanam S, Sinniah A, Ibrahim Z Cell Oncol (Dordr). 2019; 43(2):177-193.

PMID: 31677065 DOI: 10.1007/s13402-019-00477-5.